Patents by Inventor Mark A Dombroski
Mark A Dombroski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090042886Abstract: The present invention provides benzamide inhibitors of the P2X7 receptor of the formula: wherein R1-R3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.Type: ApplicationFiled: June 26, 2008Publication date: February 12, 2009Applicant: Pfizer, Inc.Inventors: MARK A. DOMBROSKI, ALLEN J. DUPLANTIER
-
Patent number: 7259171Abstract: The present invention relates to novel triazolo-pyridines of the formula I wherein R1 is fluoro; s is an integer from two to three; R2 is (C3-C6)cycloalkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, (C1-C4)alkyl, hydroxy, (C1-C6)alkoxy and (C1-C6)alkyl-(C?O)—O—; or R2 is (C1-C6)alkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, (C1-C6)alkyl, hydroxy, (C1-C6)alkoxy and (C1-C6)alkyl-(C?O)—O—; with the proviso that said compound of formula I cannot be 6-[4-(2,4-Difluoro-phenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine; or 6-[4-(3,4-Difluoro-phenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine; to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase.Type: GrantFiled: August 27, 2003Date of Patent: August 21, 2007Assignee: Pfizer Inc.Inventors: Mark A. Dombroski, Michael A. Letavic, Kim F. McClure
-
Publication number: 20070142329Abstract: The present invention provides benzamide inhibitors of the P2X7 receptor of the formula: wherein R1-R3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.Type: ApplicationFiled: February 9, 2007Publication date: June 21, 2007Inventors: Mark Dombroski, Allen Duplantier, Chakrapani Subramanyam
-
Patent number: 7186742Abstract: The present invention provides benzamide inhibitors of the P2X7 receptor of the formula: wherein R1–R3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.Type: GrantFiled: May 12, 2004Date of Patent: March 6, 2007Assignee: Pfizer IncInventors: Mark A Dombroski, Allen J. Duplantier, Chakrapani Subramanyam
-
Patent number: 7176202Abstract: The present invention provides benzamide inhibitors of the P2X7 receptor of the formula: wherein R1–R3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.Type: GrantFiled: October 27, 2005Date of Patent: February 13, 2007Assignee: Pfizer Inc.Inventors: Mark A. Dombroski, Allen J. Duplantier
-
Publication number: 20060217430Abstract: The present invention provides benzamide inhibitors of the P2X7 receptor of the formula: wherein R1-R3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.Type: ApplicationFiled: March 23, 2006Publication date: September 28, 2006Inventors: Mark Dombroski, Allen Duplantier, Chakrapani Subramanyam
-
Patent number: 7071223Abstract: The present invention provides benzamide inhibitors of the P2X7 receptor of the formula: wherein R1–R3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.Type: GrantFiled: December 30, 2003Date of Patent: July 4, 2006Assignee: Pfizer, Inc.Inventors: Mark A Dombroski, Allen J. Duplantier, Chakrapani Subramanyam
-
Patent number: 7056918Abstract: The present invention relates to novel triazolo-pyridines of the formula I wherein Het is an optionally substituted 5-membered heterocycle containing one to two heteroatoms selected from nitrogen, sulfur and oxygen wherein at least one of said heteroatoms atoms must be nitrogen; R2 is selected from the group consisting of hydrogen, (C1–C6)alkyl or other suitable substituents; R3 is selected from the group consisting of hydrogen, (C1–C6)alkyl or other suitable substituents; s is an integer from 0–5; to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, repurfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.Type: GrantFiled: March 11, 2002Date of Patent: June 6, 2006Assignee: Pfizer, Inc.Inventors: Mark A. Dombroski, Michael A. Letavic, Kim F. McClure
-
Patent number: 7037923Abstract: The present invention relates to novel alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines, to intermediates and methods for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.Type: GrantFiled: August 27, 2003Date of Patent: May 2, 2006Assignee: Pfizer, Inc.Inventors: Mark A. Dombroski, Michael A. Letavic, Kim F. McClure
-
Patent number: 7012143Abstract: The present invention relates to novel cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.Type: GrantFiled: August 27, 2003Date of Patent: March 14, 2006Inventors: Mark A. Dombroski, Michael A. Letavic, Kim F. McClure
-
Patent number: 7005523Abstract: The present invention relates to novel cycloalkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.Type: GrantFiled: August 27, 2003Date of Patent: February 28, 2006Assignee: Pfizer Inc.Inventors: Mark A. Dombroski, Michael A. Letavic, Kim F. McClure
-
Publication number: 20060040939Abstract: The present invention provides benzamide inhibitors of the P2X7 receptor of the formula: wherein R1-R3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.Type: ApplicationFiled: October 27, 2005Publication date: February 23, 2006Inventors: Mark Dombroski, Allen Duplantier
-
Patent number: 6974812Abstract: The present invention provides benzamide inhibitors of the P2X7 receptor of the formula: wherein R1-R3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.Type: GrantFiled: December 30, 2003Date of Patent: December 13, 2005Assignee: Pfizer Inc.Inventors: Mark A Dombroski, Allen J. Duplantier
-
Publication number: 20050009900Abstract: The present invention provides benzamide inhibitors of the P2X7 receptor of the formula: wherein R1-R3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.Type: ApplicationFiled: May 12, 2004Publication date: January 13, 2005Inventors: Mark Dombroski, Allen Duplantier, Chakrapani Subramanyam
-
Publication number: 20040180894Abstract: The present invention provides benzamide inhibitors of the P2X7 receptor of the formula: 1Type: ApplicationFiled: December 30, 2003Publication date: September 16, 2004Applicant: Pfizer Inc.Inventors: Mark A. Dombroski, Allen J. Duplantier
-
Publication number: 20040157877Abstract: The present invention relates to novel cycloalkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.Type: ApplicationFiled: August 27, 2003Publication date: August 12, 2004Applicant: Pfizer IncInventors: Mark A. Dombroski, Michael A. Letavic, Kim F. McClure
-
Publication number: 20040092547Abstract: The present invention relates to novel alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.Type: ApplicationFiled: August 27, 2003Publication date: May 13, 2004Applicant: Pfizer IncInventors: Mark A. Dombroski, Michael A. Letavic, Kim F. McClure
-
Publication number: 20040087615Abstract: The present invention relates to novel cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]triazolo-pyridines, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.Type: ApplicationFiled: August 27, 2003Publication date: May 6, 2004Applicant: Pfizer IncInventors: Mark A. Dombroski, Michael A. Letavic, Kim F. McClure
-
Publication number: 20040077682Abstract: The present invention relates to novel alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines, to intermediates and methods for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.Type: ApplicationFiled: August 27, 2003Publication date: April 22, 2004Applicant: Pfizer IncInventors: Mark A. Dombroski, Michael A. Letavic, Kim F. McClure
-
Publication number: 20040053958Abstract: The present invention relates to novel triazolo-pyridines of the formula I 1Type: ApplicationFiled: August 27, 2003Publication date: March 18, 2004Applicant: Pfizer Inc.Inventors: Mark A. Dombroski, Michael A. Letavic, Kim F. McClure